

Evaluation of FOXP3 and IL10 as immunosuppressant markers in pediatric Acute Lymphocytic Leukemia patients in Iraq

By Maha Kalaf Zughair

Evaluation of FOXP3 and IL10 as immunosuppressant markers in pediatric Acute Lymphocytic Leukemia patients in Iraq

Zainab Jasim Mohammed¹, Maha Kalaf Zughair^{1*}, Majid noori Humoud², Sadeq K. Ali³

¹Department of Biology, College of Sciences, University of Basrah, Basrah, Iraq

²Department of pathology analyses, College of Sciences, University of Basrah, Basrah, Iraq

³Department of Hematopathology, AL-Zahraa College of Medicine, University of Basrah, Basrah, Iraq

*Corresponding

maha.almishrey@uobasrah.edu.iq

Basrah, Iraq

ABSTRACT

Background. Increased FoxP3+ Treg levels in the TME were positively correlated with a worse prognosis in certain cancer patients. FOXP3 was significantly overexpressed in pediatric B-ALL patients, and this overexpression was associated with a worse prognosis and increased risk of disease relapse. It is unknown if children that have the condition would have different prenatal immune development. This study investigates the relationship between IL10, and immunological development in pediatric ALL.

Methods. A70 blood samples from children between the ages of 2 and 14 for both sexes were obtained from patients with Acute lymphoblastic leukemia. Furthermore, this study comprised 54 healthy controls. Were included in this study FOXP3 expression on leukemic blast cells were assessed using flow cytometry. And IL10 were assessed using ELISA test.

Results. Increased of foxp3 cells was noticed in children with ALL compared to healthy individuals significantly increased of foxp3 (mean±SD, 91.156 ± 12.255 vs. 14.88 ± 7.897pg/ml (P<0.05). In light of these findings, significant differences in the levels of foxp3 was higher in induction than consolidation stage of chemotherapy (mean±SD, 91.24± 11.078vs. 86.35±5.16.66) pg/ml (p<0.05). Additionally, it was found that the prevalence of lymphoblast that express FOXP3 was notably higher in the HR group in contrast to the SR group (mean±SD, 95.52± 5.79 vs. 42.88± 31.38) pg/ml (p<0.05). Following these findings, significant differences in the levels of foxp3 was higher in relapse than new diagnosis chemotherapy stage (mean±SD, 95.66± 5.167vs. 91.035±5.13.177) pg/ml (p<0.05). On other hand, children with ALL were also found to have significantly higher levels of IL10 in the current study when compared to healthy controls (mean±SD, 0.146 ± 0.145 vs. 0.076 ± 0.10) pg/ml (P<0.05). Following these findings, significant differences in the levels of IL10 was higher in consolidation than induction chemotherapy stage (mean±SD, 0.165± 0.084 vs.0.0720±.018) pg/ml (p<0.05), The serum level of IL-10 were evaluated in the two groups: new diagnosis and relapse cases. As in the description profile, serum levels are higher in relapse group with highly significant difference. For the parameterIL10 (P ≤0.05). The mean level of IL10 (0.130) pg/ml and (0.216) pg/ml, with (P-value =0.0001) in new diagnosis and relapse receptivity.

Conclusions. According to our findings, B-ALL patients have significant amounts of both foxp3 and IL10. This pilot study provides a novel way to look into the process mediating the

appearance of these markers in a greater number of B-ALL patients at various stages of their treatment.

Keywords: FOXP3, IL10, Acute lymphoblastic leukemia, chemotherapy

INTRODUCTION

Leukemia is a broad class of hematologic malignancies that arises from the aberrant proliferation of developing leukocytes [1].

which is used to describe a broad spectrum of hematological malignancies that are currently categorized based on molecular, morphological, cytogenetic, clinical characteristics, immunophenotype, and immunological factors the excess of white blood cells that are seen in the bloodstream of these disease patients [2]. In children and adolescents worldwide, leukemia is the most common malignancy, followed by diseases of the brain and central nervous system [3]. It is classified as either acute or chronic according to the stage of cell development, and the myeloid and lymphoid based on cell type [4]. In acute leukemias, usually, immature, abnormally differentiated leukocytes (blasts), which can be either lymphoblasts or myeloblasts, are the cells that are cancerous. Because of these blasts' capacity for clonal multiplication and proliferation, normal blood products' growth and functionality may be disrupted, leading to the replacement of healthy blood cells with cancerous ones and the manifestation of clinical signs [1]. The most common kind of treatment is chemotherapy. This activity highlights the role of the interprofessional group in leukemia diagnosis and treatment, as well as leukemia evaluation and therapy [1].

Both adults and children can be affected with acute lymphoblastic leukemia (ALL), also referred to as lymphocytic leukemia. In the bone marrow, blood, and extramedullary areas, lymphocyte precursor cells proliferate and undergo malignant transformation [5].

The immune system is a multifaceted, dynamic biological system that protects host organisms against the formation of malignancies and invasion by pathogens. Moreover, it actively contributes to organ regeneration and tissue homeostasis [6]. It comprises a wide variety of immune cell types and immunological mediators, which combine to form the innate and adaptive immune systems. It is common knowledge that the body's primary defense mechanism consists of innate immune cells. Dendritic cells (DCs), macrophages, and mast cells release immune

mediators in response to an attack on the body. These cells also perform immunological surveillance [7].

Immune system function is critical for both preventing and treating hematological malignancies and cancer [8]. Tregs have the ability to suppress antitumor immunity, which speeds up the progression of malignancies. Furthermore, there is a substantial correlation between their presence in the tumor microenvironment and a bad prognosis [9].

The Forkhead box (FOX) protein superfamily of transcriptional regulators is involved in a variety of processes, including cell division, proliferation, and survival as well as embryonic development and adult tissue homeostasis [10]. Regulatory T cells, or Tregs, are the most important immunosuppressive cells because they express the transcription factor FOXP3 (forkhead box protein). During development, the transcription factor FOXP3 determines a cell's lineage and is necessary for Treg maintenance and function [11].

Cytokines mediate important interactions between immunological and non-immune cells inside the tumor microenvironment. (TME) [12]. The highly expressed anti-inflammatory cytokine IL10 was found when Treg cytokines were studied [13]. Multifunctional immune-regulatory cytokine interleukin IL10 has anti-angiogenic and immunosuppressive properties [14].

A variety of immune cells release IL-10, a strong regulatory cytokine that has the ability to either directly or indirectly reduce inflammation by inhibiting T cells or antigen-presenting cells (APCs) [15].

Regulatory T-cell subsets, specifically T-regulatory type 1 cells (TR1) and Foxp3+ regulatory T cells (Treg cells) have been well-documented as sources of IL-10 [16]. Furthermore, IL-10 directly inhibits memory Th17 and Th2 cells while promoting the survival and functionality of Foxp3+ regulatory T cells (Tregs) [17] IL10 may have pleiotropic effects in a variety of illnesses and may be linked to the emergence of ALL [18].

METHODS

Patients and samples

A total number of 70 patients (25 newly diagnosed, 12 relapse and 21 during induction and 12 during consolidation chemotherapy). Were enrolled, aged 2 years to 14 years, along with 54 healthy controls who were the same age and gender as the study. Were included in this study

FOXP3¹ expression on leukemic blast cells were assessed using flow cytometry. And IL10 were assessed using ELISA test.

Blood sample was drawn from 70 patients in 3 cohorts of pediatric patients¹ hospitalized between July 2022 and December 2023. as a fellow:

(G1): contained 25 samples of children with newly diagnosed ALL who had not yet received therapy. (steroids or chemotherapy) is initiated.

(G2) comprised 21 samples from ALL patients receiving induction chemotherapy.

(G3) 11 samples from ALL patients receiving consolidation chemotherapy were included.

(G4) Twelve patients who had achieved full remission before experiencing a relapse. moreover, age range: 2 to 14 years. The current study also included a control group of 54 boys and girls in good health, ages 2 to 14.

Flow Cytometric Determination of foxp3

For foxp3 analysis, for immunophenotyping, cells were stained with monoclonal antibodies conjugated to , phycoerythrin (PE), consist of a processing method with three steps. /lyse/wash method was applied. In brief

First step (processing): 1- 5 ml of foxp3-PE¹ were added to 100 µl of (EDTA) whole blood tube. 2- Vortex and incubated for 15 to 30 minutes in the dark at room temperature. 3- Added 2 ml of 1x BD FACS lysing solution mixed, and left for 15 minutes in the dark, centrifuge at 300g for 5 minutes⁴ 4- Vortex and incubated for 10 minutes in dark at room temperature 5-Centrifuge at 300g for 5 minutes. 6- Added 2 to 3 ml of BD cell WASH solution and centrifuge for 5 minutes:¹ After that, data analysis was carried out using a flow cytometer (FACSC¹ anto flow cytometer with Cell Quest software; Becton Dickinson) and FlowJo X 10.0.7 software (FlowJo, Ashland, OR, USA).

Serological tests

Determination level of Human IL10 by ELISA

All serum samples were examined to detect IL10 Determination was performed by using ELISA according to (Elabscience kit, USA).

Statistical analysis

Version 26 of the (SPSS) was utilized to examine the information. Quantitative data were expressed as mean±standard deviation and median with lowest and maximum values, whereas

There was expression of qualitative data as numbers and percentages. We employed the Shapiro, Smirnov, and Kolmogorov Will examinations to evaluate the normality of the quantitative data distribution. The chi2 test was developed to look at relationships between two or more qualitative variables. The Kruskal Wallis and Mann Whitney U tests were employed to examine differences between quantitative data. A p-value of less than 0.05 indicated that a statistical association was significant.

Results

Study showed that the highest percentage of ALL patients was in the age group (2-5) years (54.3%) followed by age group (6-12) years (41.4%) whereas the lowest percentage was in patients older than 12 years (4.3%) (P-value= 0.802).

Three age categories were created within the study group: 2-5 years, 6-12 years, and < 12 years. There is Between the cases and control group, there was no noticeable difference. (P =0.802). Additionally, there is no discernible variation in the two groups' sex distribution (P = 0.538) table (1)(2).

Table (1) distribution of age between studied and control groups

Age groups	Group		Total	P-value
	Patient	Control		
2 to 5 years	38	29	67	0.802
	54.3%	53.7%	54.0%	
6to 12 years	29	24	53	
	41.4%	44.4%	42.7%	
12-18 years	3	1	4	
	4.3%	1.9%	3.2%	
Total	70	54	124	
	100.0%	100.0%	100.0%	

Table (2) distribution of sex between studied and control groups

Sex	Group		Total	P-value
	Patient	Control		
Male	44	31	75	0.538
	62.9%	57.4%	60.5%	
Female	26	23	49	
	37.1%	42.6%	39.5%	

Total	70	54	124
	100.0%	100.0%	100.0%

Flow Cytometer study

Higher percentages of foxp3 marker was shown in ALL children compared to healthy controls significantly increased percentage of foxp3 (mean±SD, 91.156 ± 12.255 vs. 14.88 ± 7.897 pg/ml, (P<0.05). In light of these results, notable variations in the foxp3 levels in consolidation was higher than induction chemotherapy stage (mean±SD, 91.24 ± 11.078 vs. 86.35 ± 5.166) pg/ml, (p<0.05). Following these findings, significant differences in the levels of foxp3 was higher in relapse than new diagnosis chemotherapy stage (mean±SD, 95.66 ± 5.167 vs. 91.035 ± 5.13177) pg/ml, (p<0.05). Another observation was that the frequency of foxp3 significantly higher in HR than in SR group (mean±SD, 95.52 ± 5.79 vs. 42.88 ± 31.38) pg/ml (p<0.05) table (3 and 4). (figure 1, 2, 3 and 7).




Figure (1) Level of Foxp3 between patient and control




Figure (2) The level of foxp3 between new and Relapse groups




Figure (3) Level of foxp3 between induction and consolidation groups

Serological tests

On other hand increased percentages of IL10 was noticed in children with ALL compared to healthy individuals significantly increased percentage of IL10 (mean±SD, 0.146 ± 0.145 vs. 0.076 ± 0.10 pg/ml ($P < 0.05$)). In light of these findings, notable variations in the IL10 levels was higher in consolidation stage than induction stage chemotherapy (mean±SD, 0.165 ± 0.084 vs. 0.0720 ± 0.018) pg/ml ($p < 0.05$), Serum levels of IL10 in risk groups, HR and SR, are comparable with No significant differences, with $p = .1655$, (table 5).

The IL-10 serum level was assessed in two groups: those with a new diagnosis and those experiencing a relapse. Serum levels are higher in the relapse group with a highly significant

difference, as indicated by the descriptive profile. Regarding the IL10 parameter. The mean level of IL10 (0.130) pg/ml and (0.216) pg/ml, with (P-value =0.0001) in new diagnosis and relapse receptivity. Table (4), IL-10 serum levels in the two risk groups HR and SR, are comparable with no discernible differences $p=0.1655$, (table 6). (figures 3, 4, 5)




Figure (4) Serum level of IL10 between patient and Control groups




Figure (5) Serum level of IL10 between new diagnosis and relapse groups




Figure (6) Serum level of IL10 between induction and consolidation groups

Table (3) Level of Foxp3 in patient among study groups and control

Marker	Control (n=54)				Patient(n=70)				P – value
	Mean	SD	Minimum	Maximum	Mean	SD	Minimum	Maximum	
Foxp3	14.88	7.89	2.04	36.84	91.15	12.25	17.51	100.00	0.0001
	New (n=25)				Relapse(N=12)				
	91.03	13.17	17.51	99.51	95.66	5.16	87.27	100.00	0.0001
	induction (n=12)				Consolidation (n=21)				
	86.35	16.66	53.97	100.00	91.24	11.078	60	100.00	0.0001

* Kruskal Wallis Test

Table (4) The level of foxp3 in risk groups

Risk group	N	Foxp3			
		Mean	SD	Minimum	Maximum

High RG	19	95.52	5.79	77.78	99.51
Stander RG	6	42.88	31.38	17.51	95.5
P-value	0.0001				

* Mann-Whitney U Test

Table (5) Serum level of IL10 in patient, control, new diagnosis , relapse, induction and consolidation groups


IL	Control(N=54)				Patient (N=70)				p-value
	Mean	SD	Minimum	Maximum	Mean	SD	Minimum	Maximum	
IL10	0.076	0.10	0.05	0.6	0.146	0.145	0.05	0.7	0.0001
	New (n=25)				Relapse(N=12)				
	0.130	0.160	0.05	0.68	0.216	.218	0.06	0.71	0.0001
	induction (n=12)				Consolidation (n=21)				
	0.0720	0.018	0.06	0.13	0.165	0.084	0.07	0.37	0.216

* Kruskal Wallis Test


Table (6) Serum level of IL10 in risk groups

Risk group	N	IL10			
		Mean	SD	Min	Max
High RG	19	0.1222	0.143	0.0532	0.6781
Stander RG	6	0.1533	0.211	0.0666	0.6321
p-value	0.1655				


Mann-Whitney U Test , $p \leq 0.05$



a- FOXP3 in control group



b- FOXP3 in induction group



c- FOXP3 in consolidation group

Figure 7. FOXP3 in different groups of the study.

DISCUSSION

Since Tregs express forkhead box protein 3 (Foxp3), a transcription factor essential for suppressive action and the production of immune regulatory molecules including the anti-inflammatory cytokine IL-10, Foxp3 is believed to be a distinct hallmark of Tregs [19,20].

According to the current study, the majority of pediatric cases of acute lymphoblastic leukemia fall into the 2–5 and 6–12 year age ranges, this result was agreed with [21-25].

In this investigation, we discovered a distinct difference in the expression of FOXP3, which was considerably higher in patients with ALL than in the control group.

The mean level of FOXP3 in patient (91.156) pg/ml and control (14.880) pg/ml, with P-value <0.05. The current investigation's findings, which other researchers corroborated [26-29].

1 Showed that the frequency of FOXP3 -expressing lymphoblast was significantly greater in the HR group than in the SR group. The mean HR (94.42) pg/ml was higher than the stander risk group's mean (42.79) with p- value ≤0.05, This outcome was accepted with [30].

In our investigation, discovered that the newly diagnosed patients had noticeably high level of FOXP3(91.03)pg/ml and induction stage the mean (86.35)pg/ml and in consolidation (91.247) P-value <0.05. This finding is concurred with Salem *et al.*[31] and Idris *et al.*[32], In our investigation, we hypothesized that FOXP3 is connected to the suppression of cancer cell growth. This could be triggered by the effects of chemotherapy drugs.

The present study was used Enzyme-linked immunosorbent assay (ELISA) test to detection IL10.

The current study was showed, The patient group had higher IL-10 concentrations than the control group., The mean serum level of IL10 in patients(0.146) pg/ml and control (0.076) with P-value <0.05. This outcome was accepted with [33][34]

Significant variations in the serumIL10 levels at the time of diagnosis and control are observed in our investigation. the mean serum level of IL10 in new diagnosis (0.130) pg/ml and control (0.076). This result was agreed with [33-35].

9 Following these findings, while the opposite effects with decreased IL-10 was seen after 3 month induction (P=0.001), The mean serum level of IL10 in 3 month (0.072) pg/ml, due to corticosteroid effects, which alter metabolism and produce an increase in food intake [36,37]. The glucocorticoid receptor is a binding site for steroids, which inhibits the synthesis of cytokines [38].

Significant variations in serum IL-10 levels are observed in our study following three months of induction rather than consolidation. The mean serum level of IL10 in induction(0.072) pg/ml and consolidation (0.165) pg/ml (P=0.001). However, the opposite results were observed with decreased IL-10.

In our study we observe In our investigation, we find that the serum IL10 levels after relapse are significantly different from the initial diagnosis and The mean serum level of IL10 in new diagnosis (0.130) pg/ml and relapse (0.2160) pg/ml with P-value ≤ 0.05 . This outcome was accepted [39]. Compared to initial ALL, IL10 was higher in ALL patients with disease recurrence.

Conclusion

According to our findings, B-ALL patients have significant amounts of both foxp3 and IL10. This pilot study provides a novel way to look into the process mediating the appearance of these markers in a greater number of B-ALL patients at various stages of their treatment.

Disclosure

None

REFERENCES

1. CHENNAMADHAVUNI, Adithya, et al. Continuing education activity. *National Library of Medicine*, 2021, 2.
2. WHITELEY, Andrew E., et al. Leukaemia: a model metastatic disease. *Nature Reviews Cancer*, 2021, 21.7: 461-475.
3. AL-HASHIMI, Muzahem MY. Incidence of childhood leukemia in Iraq, 2000-2019. *Asian Pacific Journal of Cancer Prevention: APJCP*, 2021, 22.11: 3663.
4. LYENGAR, V.; SHIMANOVSKY, A. Leukemia. *StatPearls*. 2021.
5. SHEYKHHASAN, Mohsen; MANOOCHEHRI, Hamed; DAMA, Paola. Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study. *Cancer gene therapy*, 2022, 29.8: 1080-1096.
6. BOCHAROV, Gennady, et al. Mathematical modeling of the immune system in homeostasis, infection and disease. *Frontiers in immunology*, 2020, 10: 510210.
7. LI, Lisha, et al. Pyroptosis, a new bridge to tumor immunity. *Cancer science*, 2021, 112.10: 3979-3994.
8. KASAKOVSKI, Dimitri; XU, Ling; LI, Yangqiu. T cell senescence and CAR-T cell exhaustion in hematological malignancies. *Journal of hematology & oncology*, 2018, 11: 1-9.
9. KIM, Jung-Ho; KIM, Beom Seok; LEE, Sang-Kyou. Regulatory T cells in tumor microenvironment and approach for anticancer immunotherapy. *Immune network*, 2020, 20.1.
10. DENG, Guoping, et al. Foxp3 post-translational modifications and Treg suppressive activity. *Frontiers in immunology*, 2019, 10: 486798.
11. MALVIYA, Vanshika, et al. Regulatory T-cell stability and functional plasticity in health and disease. *Immunology and Cell Biology*, 2023, 101.2: 112-129.
12. MASCAUX, Céline, et al. Immune evasion before tumour invasion in early lung squamous carcinogenesis. *Nature*, 2019, 571.7766: 570-575.

13. XU, Yingxi, et al. Regulatory T cells promote the stemness of leukemia stem cells through IL10 cytokine-related signaling pathway. *Leukemia*, 2022, 36.2: 403-415.
14. SHEIKHPOUR, Elnaz, et al. A survey on the role of interleukin-10 in breast cancer: A narrative. *Reports of biochemistry & molecular biology*, 2018, 7.1: 30.
15. OUYANG, Wenjun, et al. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. *Annual review of immunology*, 2011, 29: 71-109.
16. YOGEV, Nir, et al. CD4+ T-cell-derived IL-10 promotes CNS inflammation in mice by sustaining effector T cell survival. *Cell Reports*, 2022, 38.13.
17. COOMES, S. M., et al. CD4+ Th2 cells are directly regulated by IL-10 during allergic airway inflammation. *Mucosal immunology*, 2017, 10.1: 150-161.
18. DE DEUS, Dayse Maria Vasconcelos; DE SOUZA, Paulo Roberto Eleutério; MUNIZ, Maria Tereza Cartaxo. High FLT3 expression and IL10 (G1082A) polymorphism in poor overall survival in calla acute lymphoblastic leukemia. *Molecular biology reports*, 2013, 40: 1609-1613.
19. HURRELL, Benjamin P., et al. PD-L2 controls peripherally induced regulatory T cells by maintaining metabolic activity and Foxp3 stability. *Nature Communications*, 2022, 13.1: 5118.
20. LIU, Chao, et al. A panel containing PD-1, IL-2R α , IL-10, and CA15-3 as a biomarker to discriminate breast cancer from benign breast disease. *Cancer management and research*, 2018, 1749-1761.
21. KHAN, MASUMA, et al. Platelet indices as markers for remission in ALL during induction of remission: an experience of 52 cases. *Bangladesh J Child Health*, 2020, 44.1: 34-9.
22. BADR, Zainab, et al. Evaluation of VEGF-A in relation to childhood acute lymphoblastic leukemia (in Basrah, Iraq): Evaluation of VEGF-A

in relation to childhood acute lymphoblastic leukemia (in Basrah, Iraq). *Iraqi National Journal of Medicine*, 2021, 3.1: 39-44.

23. DAI, Qingkai, et al. Combined use of peripheral blood blast count and platelet count during and after induction therapy to predict prognosis in children with acute lymphoblastic leukemia. *Medicine*, 2021, 100.15: e25548.
24. ALWAN, DUAA R.; JAMALLUDEEN, NIDHAM M.; AL-SALAIT, SADEQ KA. A SURVEY IN SERUM LEVEL OF IL12, IL23 AND IL27 IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN PRE-AND POST-CHEMOTHERAPY. *PLANT CELL BIOTECHNOLOGY AND MOLECULAR BIOLOGY*, 2021, 22.61-62: 66-71.
25. MUSTAFA, Rasha Adnan; JASIM, Hanadi Abdulqader; AL-SALAIT, Sadeq Khalaf Ali. Quantitative determination of serum level of TLR4, TLR7 and TLR9 in pediatric acute lymphoblastic leukemia (ALL) patients in Basrah, Iraq. *Biomedical and Pharmacology Journal*, 2021, 14.4: 2255-2260.
26. NIEDŹWIECKI, M., et al. CD4+ CD25 high CD127 low/-FoxP 3+ Regulatory T-Cell Population in Acute Leukemias: A Review of the Literature. *Journal of immunology research*, 2019, 2019.
27. JINGJING, L. I., et al. Ratio of Treg to Th17 cells in peripheral blood of children with B-cell acute lymphoblastic leukemia. *Chinese Journal of Laboratory Medicine*, 2021, 726-730.
28. BHATTACHARYA, Kaushik; CHANDRA, Sarmila; MANDAL, Chitra. Critical stoichiometric ratio of CD 4+ CD 25+ FoxP3+ regulatory T cells and CD 4+ CD 25- responder T cells influence immunosuppression in patients with B-cell acute lymphoblastic leukaemia. *Immunology*, 2014, 142.1: 124-139.
29. LIU, Si-Xi, et al. Preliminary investigation on the abnormal mechanism of CD4+ FOXP3+ CD25high regulatory T cells in pediatric B-cell acute lymphoblastic leukemia. *Experimental and Therapeutic Medicine*, 2018, 16.2: 1433-1441.
30. EL-MAADAWY, Eman A., et al. Genetic variation in FOXP3 and ROR- γ genes in pediatric acute lymphocytic leukemia (ALL) patients: correlation with associated cytokines. *Discover Oncology*, 2022, 13.1: 86.

31. SALEM, Mohamed Labib, et al. Chemotherapy alters the increased numbers of myeloid-derived suppressor and regulatory T cells in children with acute lymphoblastic leukemia. *Immunopharmacology and Immunotoxicology*, 2018, 40.2: 158-167
32. IDRIS, Siti-Zuleha, et al. Increased regulatory T cells in acute lymphoblastic leukemia patients. *Hematology*, 2015, 20.9: 523-529.
33. YAN, Yuheng, et al. Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity. *Journal of hematology & oncology*, 2022, 15.1: 104.
34. MAGALHÃES-GAMA, Fábio, et al. Imbalance of chemokines and cytokines in the bone marrow microenvironment of children with b-cell acute lymphoblastic leukemia. *Journal of Oncology*, 2021, 2021: 1-9.
35. MOHAMMED, Fatima Mallalah; FAHD, Morooj Ali; JASSIM, Nabaa Ali. Levels of Interleukin-10 in Iraqi Childhood Acute Lymphoblastic Leukemia after Chemotherapy. *Indian Journal of Forensic Medicine & Toxicology*, 2020, 14.2.
36. SKOCZEN, Szymon; SURMIAK, Marcin; STROJNY, Wojciech. Survivors of acute lymphoblastic leukemia and body mass changes. *Expert Opinion on Drug Safety*, 2010, 9.1: 65-77.
37. GORAN, Michael I. Metabolic precursors and effects of obesity in children: a decade of progress, 1990–1999. *The American journal of clinical nutrition*, 2001, 73.2: 158-171.
38. MALCZEWSKA, Marta, et al. Recent advances in treatment options for childhood acute lymphoblastic leukemia. *Cancers*, 2022, 14.8: 2021.
39. WU, Shuling, et al. Cytokine/cytokine receptor gene expression in childhood acute lymphoblastic leukemia: correlation of expression and clinical outcome at first disease recurrence. *Cancer: Interdisciplinary International Journal of the American Cancer Society*, 2005, 103.5: 1054-1063.